-
Mashup Score: 6Statins in NAFLD: Taking a Closer Look at Benefits - 2 year(s) ago
Statins could have multiple benefits in NAFLD, but there has been little insight into how they may be exerting such effects.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0International Liver Congress - 2 year(s) ago
Highlights from The International Liver Congress, including perspectives and interviews with leading researchers and clinicians.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Read the latest news from the International Liver Congress 2022, including perspectives and interviews with leading researchers and clinicians. https://t.co/REAmpueZQl #ILC2022 #gastroenterology https://t.co/G3eLNUdAXi
-
-
Mashup Score: 0
LONDON — Lower fatigue scores at baseline correlated with adverse clinical events among patients with advanced nonalcoholic steatohepatitis, according to research presented at the International Liver Congress.“Fatigue is very common in patients with NAFLD. In other diseases, fatigue is associated with adverse outcomes, including higher mortality,” Zobair M. Younossi, MD, MPH,
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Lower #fatigue scores at baseline correlated with adverse clinical events among patients with advanced #NASH, according to research presented at #ILC2022 @EASLnews #MedTwitter #Hepatology #GITwitter https://t.co/vbmKdmuqY5
-
-
Mashup Score: 0Phase 3 data shows bulevirtide benefit in hepatitis D - 2 year(s) ago
“For us in the hepatitis D field, it is a really exciting time; it’s completely novel data and game-changing for patients.”
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
Bulevirtide may be a potential cure for hepatitis D in some patients, according to MYR301 trial. https://t.co/L2QC0tl3Xa #ILC2022 https://t.co/3A0bYv9WIb
-
-
Mashup Score: 1Fatty Liver Disease Drives Rise in Liver Cancer Deaths - 2 year(s) ago
The steep increase in liver cancer deaths is due to the rising rate of NAFLD, rather than alcoholic liver disease or hepatitis B or C, and is mostly driven by the obesity and type 2 diabetes epidemics.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NAFLD has driven an increase in deaths from liver cancer over the past decade, overtaking alcoholic liver disease, hepatitis B, and hepatitis C, according to an analysis. #livertwitter https://t.co/cNYu73Cztn #ILC2022
-
-
Mashup Score: 0
LONDON — Cirrhosis severity, infections and mortality outcomes were worse for patients in low to middle-income countries, due in part to poor access to liver transplant and ICU facilities, according to data presented here. “We have health care disparities as well as differing populations and diseases that cause cirrhosis around the world,” Jasmohan S. Bajaj, MD, associate
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
“We have #healthcare #disparities as well as differing populations and diseases that cause #cirrhosis around the world. Current data usually focus on few regions rather than providing a global perspective,” @JasmohanBajaj told Healio. #ILC2022 @EASLnews https://t.co/ZKhmVteggB
-
-
Mashup Score: 4
LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic steatohepatitis, according to late-breaking research presented at the International Liver Congress. “The primary and key secondary endpoints from the study were achieved,” Stephen Harrison, MD, medical director for Pinnacle Clinical Research in San Antonio and visiting
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with #NASH, according to late-breaking research presented at #ILC2022 @EASLnews #MedTwitter #Hepatology https://t.co/G0O6DWN52c
-
-
Mashup Score: 0Ozempic boosts cardiometabolic markers, falls short for fibrosis in NASH-related cirrhosis - 2 year(s) ago
LONDON — Ozempic improved cardiometabolic parameters and markers of liver injury yet failed to improve liver fibrosis in patients with nonalcoholic steatohepatitis and compensated cirrhosis, according to late-breaker data presented here.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI: #Ozempic boosts cardiometabolic markers, falls short for #fibrosis in #NASH-related #cirrhosis #ILC2022 @EASLnews #MedTwitter https://t.co/3rp24mlpSx
-
-
Mashup Score: 2‘Strong support, political will’ needed to achieve global HBV, HCV elimination goals - 2 year(s) ago
LONDON —Although progress has been made, nearly 12 million individuals will die early from preventable hepatitis B and hepatitis C deaths without additional interventions, according to research presented at the International Liver Congress.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
“Globally, and at the continent level, viral #hepatitis remains a public health threat through 2030, based off our current trends," @SarahJBlach of @CDAFound said at #ILC2022 @EASLnews #MedTwitter #Hepatology https://t.co/tpb7zM9Q5a
-
-
Mashup Score: 0
LONDON — Magnetic resonance elastography in combination with the fibrosis-4 index was a better predictor of significant fibrosis in patients with nonalcoholic fatty liver disease vs. other noninvasive techniques, noted a presenter here. “NALFD patients with significant fibrosis — defined as those who have stage 2 or higher — are candidates for pharmacological
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI from #ILC2022: MRE plus FIB-4 bests MAST, FAST to ‘rule in or rule out’ stage 2 #fibrosis in #NAFLD @EASLnews @DrLoomba #MedTwitter #Hepatology https://t.co/Ev7e8I9YUC
-
#Statins could have multiple benefits in #NAFLD, but there has been little insight into how they may be exerting such effects. https://t.co/6QiTc6s7Qh #ILC2022 #LiverTwitter https://t.co/m4bALg6aS8